Galectin Therapeutics (GALT) Phase 2b NASH-CX Trial Did Not Reach Primary Endpoint
Tweet Send to a Friend
(Updated - December 5, 2017 8:19 AM EST)Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
